Abstract 185P
Background
LIF is an interleukin 6 class cytokine that plays a crucial role in the development of many solid tumors. Herein, we identify the elusive role of LIF in clear cell renal cell carcinoma (ccRCC) and its impact on tumor immune microenvironment.
Methods
The human cancer genome atlas (TCGA) was utilized to obtain ccRCC clinicopathological and expression data. The prognostic utility of LIF expression in ccRCC was evaluated using univariate and multivariate Cox logistic regression analysis. Co-expressed genes were explored using LinkedOmics and their biological roles were identified using gene set enrichment analysis (GSEA) through KEGG pathways terminology. The immune microenvironment was evaluated using Tumor IMmune Estimation Resource (TIMER 2.0). Correlations between LIF expression and immune-related genes were obtained using the Gene Expression Profiling Interactive Analysis (GEPIA).
Results
High LIF expression is associated with shortened overall survival (HR: 1.828, 95% CI: 1.358-2.460, P < .0001) in TCGA ccRCC cohort. Multivariate Cox logistic regression analysis identified LIF expression as an independent prognostic variable (HR: 0.48, 95% CI: 0.303-0.759, P = .002). GSEA showed enrichment in IL-17, TNF, JAK-STAT and NF-kB signaling pathways besides cytokine-cytokine receptor interaction, transcriptional misregulation in cancer, complement and coagulation cascades. LIF expression is positively corelated with immunosuppressive cellular elements including Tregs (ρ = 0.14, Q = 0.012), M2 macrophages (ρ = 0.25, Q < .0001), and myeloidderived suppressor cells (ρ = 0.18, Q value < .001). In addition, LIF corelated significantly with Tregs-related genes including FOXP3 (ρ = 0.28, P < .0001), CCR8 (ρ = 0.23, P < .0001), and TGF-β (ρ = 0.38, P < .0001). M2 macrophages-related genes were also significantly corelated with LIF expression as in CD163 (ρ = 0.30, P < .0001), VSIG4 (ρ = 0.27, P < .0001), and MS4A4A (ρ = 0.24, P < .0001). Immune check points genes were also influenced by LIF expression including CTLA4 (ρ = 0.25, P < .0001) and LAG3 (ρ = 0.21, P < .0001).
Conclusions
LIF upregulation corelates with poor prognosis in ccRCC and induces an immune suppressed microenvironment.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
136P - Circadian rhythm positioned chronomodulated-SBRT with Cancer associated fibroblast elimination theranostic treatment to harmonize resistant TFG-Beta stromal microenvironment in conjunction with PDL-1 based immunotherapy in disseminated cancers-Concept randomised study.
Presenter: G Lohith
Session: Poster Display
137P - First-in-human results from a Phase I dose-escalation study of VSV-GP (BI 1831169) in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster Display
138P - Generation of frameshift mutated TGF_R2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF
Presenter: Else Inderberg
Session: Poster Display
139P - Safety and clinical activity of a novel anti-CCR8 antibody (LM-108) as a single agent or in combination with pembrolizumab in patients with advanced solid tumors: Results of phase 1 study
Presenter: Alexander Starodub
Session: Poster Display
140P - Eliciting mAbs targeting MHC-bound peptides with a novel antibody discovery platform
Presenter: Elli Sandberg
Session: Poster Display
141P - An IgE antibody targeting the melanoma-associated Chondroitin Sulfate Proteoglycan 4
Presenter: Lais Cristina Palhares
Session: Poster Display
142P - Identifying novel immunotherapy targets using machine learning and ex vivo validation
Presenter: Marcellus Augustine
Session: Poster Display
143P - Advancing Cancer Immunotherapy via HLA-G Pathway Modulation with UCB4594
Presenter: Ann WHITE
Session: Poster Display
144P - Discovery of CBO421, a first-in-class Drug Fc-Conjugate (DFC), targeting CD73 in Cancer
Presenter: Simon Döhrmann
Session: Poster Display
145P - An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: ZONG SEAN JUO
Session: Poster Display